Videos

Because vasculitis can manifest in various ways, Matthew Koster, MD, talks about identifying Granulomatosis with polyangiitis and other forms of the disease.

Tanaz Kermani, MD, MS, talks about the current state of vasculitis care and the latest research in the field.

Dr. Kenneth J. Warrington led the panel in discussing various topics in rheumatology.

Jeff Peterson, MD, explains the importance of the recent FDA announcement granting priority review of the Supplemental Biologics License Application for concomitant use of pegloticase injection (KRYSTEXXA) plus methotrexate for patients with uncontrolled gout.

Advice to rheumatologists in terms of staying up to date on newer treatment options entering the market for lupus.

Novel therapies in the pipeline that demonstrate potential advantages when used as treatment for systemic lupus erythematosus and lupus nephritis.

John Tesser, MD, closes the discussion with unmet needs in the PsA treatment landscape, as well as what he hopes to see in the future.

Expert panelists share tips for boosting patient compliance among patients with psoriatic arthritis.

Three colleagues share insights into their evolving approaches regarding the management of patients with psoriatic arthritis who test positive for COVID-19.

Expert John Sergent shares insight on his best practices treating patients with autoimmune diseases.

Recommendations for monitoring patients on novel therapies used to manage lupus nephritis and making decisions to taper or stop treatment.

The rationale for treating lupus nephritis with novel therapies such as belimumab and voclosporin.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, emphasize the important of vaccination against COVID-19 for patients with psoriatic arthritis.

A panel of experts and colleagues recall the indicators and steps that need to be taken when changing PsA therapies.

The rationale for using a newer monoclonal antibody therapy, anifrolumab, to manage patients with systemic lupus erythematosus.

Indications for belimumab, a monoclonal antibody, as therapy for patients with systemic lupus erythematosus.

Three experts discuss measurement of outcomes for psoriatic arthritis management and what a “successful” treatment looks like.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, profile classes of interleukin inhibitors and the potential benefits for patients with psoriatic arthritis.

Before closing out their discussion on psoriatic arthritis management, two experts consider how the COVID-19 pandemic has affected their practice.

Daniel J. Lovell, MD, MPH, explains the recent ACR guidelines updates regarding the treatment and management of juvenile idiopathic arthritis and the clinical significance of the changes.

Resources that can help educate patients with lupus about their diagnosis and encourage them to take a more proactive role in self-care.

Types of tests used to evaluate patients for signs of lupus or disease progression.

Roy Fleischmann, MD, discusses the usage of biosimilars in the United States and hypothesizes about what is in store for the future.

Roy Fleischmann, MD, examines the current state of biosimilars as it relates to rheumatologists in the United States.

Roy Fleischmann, MD, explains the history of biosimilars in rheumatology as well as implementing biosimilars in the United States.

The panel explains the many conventional DMARDs that can be used to treat psoriatic arthritis, as well as their role in management.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, talk about the importance of shared decision-making in the treatment of psoriatic arthritis.

Thought leaders discuss differences in recommendations between guidelines for the management of psoriatic arthritis.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, discuss the common triggers patients with psoriatic arthritis and the importance of stress management.